sumatriptan has been researched along with cromakalim in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Karagholi, MA; Amin, FM; Ashina, M; Ghanizada, H; Hansen, JM; Larsson, HBW; Olesen, J; Skovgaard, LT | 1 |
| Ashina, M; Christensen, SL; Ernstsen, C; Guo, S; Hay-Schmidt, A; Kristensen, DM; Olesen, J | 1 |
1 trial(s) available for sumatriptan and cromakalim
| Article | Year |
|---|---|
Levcromakalim, an Adenosine Triphosphate-Sensitive Potassium Channel Opener, Dilates Extracerebral but not Cerebral Arteries.
Topics: Adult; Cromakalim; Double-Blind Method; Female; Headache; Humans; Ion Channel Gating; Male; Meningeal Arteries; Middle Cerebral Artery; Organ Specificity; Potassium Channels; Sumatriptan; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents; Young Adult | 2019 |
1 other study(ies) available for sumatriptan and cromakalim
| Article | Year |
|---|---|
PACAP signaling is not involved in GTN- and levcromakalim-induced hypersensitivity in mouse models of migraine.
Topics: Animals; Calcitonin Gene-Related Peptide; Cromakalim; Disease Models, Animal; Drug Hypersensitivity; Mice; Migraine Disorders; Nitroglycerin; Pituitary Adenylate Cyclase-Activating Polypeptide; Signal Transduction; Sumatriptan | 2022 |